Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0608 • ACR Convergence 2022
Wnt Pathway Regulators R-spondin 3 and Dickkopf-related Protein 3 Demarcate a Transcriptional Gradient That Drives Synovial Fibroblast Inflammatory Pathology in Rheumatoid Arthritis
Alisa Mueller¹, Angela Zou², SABA NAYAR³, Emily Taylor³, Triin Major³, David H Gardner³, Gerald FM Watts¹, Adam Croft³, Roche Fibroblast Network Consortium⁴, Andrew Filer³, Christopher Buckley⁵, Kevin Wei⁶, ilya Korsunsky¹, Soumya Raychaudhuri¹ and Michael Brenner⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴Roche, Basel, Switzerland, ⁵University of Oxford, Oxford, United Kingdom, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Synovial fibroblasts are key players in rheumatoid arthritis (RA) where they secrete inflammatory cytokines and directly instigate cartilage and bone destruction. However, most treatments…
Abstract Number: 0626 • ACR Convergence 2022
Elucidating the Expression and Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Human Rheumatoid Arthritis Synovial Fibroblasts and a Rat Adjuvant-induced Arthritis Model
Meena Afroze Shanta¹, Farheen Sultan Shaikh², Bhanupriya Madarampalli³ and Salahuddin Ahmed², ¹College of Pharmacy and Pharmaceutical Science, Washington State University, Spokane, WA, ²Washington State University, Spokane, WA, ³University of Washington, Bellevue, WA
Background/Purpose: Proprotein convertase subtilisin/Kexin type-9 (PCSK9) is the most recognized serine protease for its pathological role in cardiovascular diseases, however, its role in inflammatory diseases,…
Abstract Number: 0761 • ACR Convergence 2022
Identification of Outcome Domains in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis and Polymyalgia Rheumatica: A Scoping Review by the OMERACT IrAE Working Group
Nilasha Ghosh¹, Nina Couette², Wouter van Binsbergen³, Sophia Weinmann⁴, Bridget Jivanelli¹, Beverley Shea⁵, Anne Bass⁶, Karolina Benesova⁷, Clifton O. Bingham III⁸, Cassandra Calabrese⁹, Laura C. Cappelli¹⁰, Karmela Kim Chan¹, Ernest Choy¹¹, Dimitrios Daoussis¹², Susan Goodman¹, Marie Hudson¹³, Shahin Jamal¹⁴, Jan Leipe¹⁵, Maria A. Lopez-Olivo¹⁶, Maria Suarez-Almazor¹⁷, Conny van der Laken¹⁸, Alexa Meara¹⁹, David Liew²⁰ and Marie Kostine²¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Internal Medicine. Division of Rheumatology & Immunology, The Ohio State University, Columbus, OH, ³Amsterdam Rheumatology and Immunology Center, Department of Rheumatology & Clinical Immunology, Amsterdam University Medical Center location DBL, Amsterdam, Netherlands, ⁴Department of Rheumatology & Immunology, Duke University, Durham, NC, ⁵School of Epidemiology and Public Health, University of Ottawa, Ottawa, ⁶Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁷University Hospital Heidelberg, Heidelberg, Germany, ⁸Johns Hopkins University, Baltimore, MD, ⁹Cleveland Clinic Foundation, Cleveland Heights, OH, ¹⁰Johns Hopkins School of Medicine, Baltimore, MD, ¹¹Division of Infection and Immunity, CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ¹²Department of Rheumatology, University of Patras Medical School, Patras University Hospital, Patras, Greece, ¹³McGill University, Montréal, QC, Canada, ¹⁴University of British Columbia, Vancouver, BC, Canada, ¹⁵Division of Rheumatology, Department of Medicine V, University Hospital Mannheim, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany, ¹⁶The University of Texas, MD Anderson Cancer Center, Houston, TX, ¹⁷MD Anderson Cancer Center, Houston, TX, ¹⁸Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers – location VUMC, Amsterdam, Netherlands, ¹⁹The Ohio State University Wexner Medical Center, Columbus, OH, ²⁰Austin Health, Heidelberg, Australia, ²¹Pellegrin Hospital, University Hospital of Bordeaux, Rheumatology, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICI), increasingly used cancer therapeutics, can cause off-target inflammatory effects called immune-related adverse events (irAEs), including ICI-induced inflammatory arthritis (ICI-induced IA)…
Abstract Number: 0848 • ACR Convergence 2022
Postoperative Flares and Peri-arthroscopic Management of Immunosuppressive Medications in Patients with Rheumatic Disease
Kinjal Vasvada¹, Dhruv Shankar¹, Amanda Avila¹, Charles Lin¹, David Marulanda², Laith Jazrawi¹ and Jonathan Samuels³, ¹NYU Langone Health, New York, NY, ²NYU Langone Health, Philadelphia, ³NYU Langone, Rye Brook, NY
Background/Purpose: To determine the rate and characteristics of postoperative flares in rheumatic disease patients undergoing arthroscopic surgery, and the role of perioperative immunosuppression (IS) management…
Abstract Number: 0898 • ACR Convergence 2022
Risk of Aortic Stenosis and Undergoing Aortic Valve Replacement in Rheumatoid Arthritis: An Underrecognized Cardiovascular Complication
Tate Johnson¹, Yangyuna Yang², Chetaj Mahabir², Andrew Goldsweig², Punyasha Roul³, Joshua Baker⁴, Brian Sauer⁵, Grant Cannon⁶, Ted Mikuls⁷ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶Retired, Salt Lake City, UT, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Valvular carditis is reported as a rare extra-articular manifestation of rheumatoid arthritis (RA). In animal models with coexistent inflammatory arthritis, pro-inflammatory infiltrates of T…
Abstract Number: 0914 • ACR Convergence 2022
The Impact of Autoantibodies (RF and ACPA) on the Efficacy of Biological Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Meta-analysis of Randomized Controlled Trials
Kaoru Takase-Minegishi¹, Stephan Böhringer², Jackie Nam³, Yuko Kaneko⁴, Frank Behrens⁵, Saedis Saevarsdottir⁶, Jacqueline Detert⁷, Marjatta Leirisalo-Repo⁸, Désirée van der Heijde⁹, Robert Landewé¹⁰, Sofia Ramiro¹¹ and Diane van der Woude¹², ¹Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Yokohama, Japan, ²Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, Leiden, Netherlands, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, United Kingdom, ⁴Keio University School of Medicine, Tokyo, Japan, ⁵CIRI/Rheumatology and Fraunhofer Institute, Translational Medicine and Pharmacology ITMP, Goethe University, Frankfurt, Germany, ⁶Division of Clinical Epidemiology, Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden and Faculty of Medicine, University of Iceland, Stockholm, Sweden, ⁷Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁸Department of Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ¹⁰Amsterdam University Medical Center, Meerssen, Netherlands, ¹¹Leiden University Medical Center, Leiden, Netherlands, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The impact of autoantibodies on the efficacy of bDMARDs in patients with rheumatoid arthritis (RA) is not yet clear. Despite the fact that this…
Abstract Number: 0930 • ACR Convergence 2022
Delayed Response to Methotrexate Treatment in Rheumatoid Arthritis Patients Receiving Folic Acid Supplementation
Alberto Sulli, Tamara Vojinovic, Lercara Adriano, Emanuele Gotelli, sabrina Paolino, Alessandri Elisa and Maurizio Cutolo, Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy
Background/Purpose: MTX is the first line conventional synthetic DMARD (csDMARD) for the treatment of rheumatoid arthritis (RA), and folic acid (FA) supplementation is frequently co-prescribed…
Abstract Number: 1122 • ACR Convergence 2022
Short Peripheral Blood Leukocyte Telomere Length in Rheumatoid Arthritis – Interstitial Lung Disease
Pierre-Antoine Juge¹, Tracy Doyle², Seoyeon Lee³, Avram Walts⁴, Anthony Esposito⁵, Sergio Poli de Frias⁶, Ritu R. Gill⁷, Hiroto Hatabu⁸, Mizuki Nishino⁸, Michael Weinblatt⁹, Nancy A. Shadick⁶, Kristen Demoruelle¹⁰, Ivan O. Rosas¹¹, Benjamin granger¹², Kevin D Deane¹³, Bruno Crestani¹⁴, Paul Wolters¹⁵, Philippe Dieude¹⁶ and Joyce Lee¹³, ¹Rheumatology department, Bichat Hospital, Paris, France, ²Brigham and Women's Hospital, Boston, MA, ³Department of Medicine, University of California, San Francisco, CA, ⁴Department of medicine, National Jewish Hospital, Denver, CO, ⁵Brigham and Women's Hospital, Department of Medicine, Boston, MA, ⁶Department of Medicine, Brigham and Women's Hospital, Boston, MA, ⁷Beth Israel Deaconess Medical Center, Radiology Department, Boston, MA, ⁸Department of Radiology, Brigham and Women's Hospital, Boston, MA, ⁹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ¹⁰Department of Medicine, University of Colorado, Denver, CO, ¹¹Baylor College of Medicine, Houston, TX, ¹²Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique, PEPITES, F75013, Paris, France, Paris, France, ¹³University of Colorado Denver Anschutz Medical Campus, Denver, CO, ¹⁴Hopital Bichat, Paris University, Paris, France, ¹⁵UCSF, SF, ¹⁶Université Paris Cité, Paris, France
Background/Purpose: Shortened telomere lengths (TL) have been associated with interstitial lung disease (ILD), in particular idiopathic pulmonary fibrosis (IPF). Given the phenotypic overlap between IPF…
Abstract Number: 1236 • ACR Convergence 2022
Reduced Inflammation Following 4-weeks TNF-α Inhibitor Treatment Restore Aberrant Cerebral Pain Processing in Rheumatoid Arthritis Patients: A Randomized Double-Blind Placebo-Controlled fMRI Study
Angelica Sandström¹, Peter Fransson², Reem Altawil³, Eva Kosek⁴ and Jon Lampa³, ¹Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden; Department of Radiology, Massachusetts General Hospital, Boston, MA, ²Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institutet, Stockholm, Sweden; Department of Gastroenterology, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁴Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Neuroradiology, Karolinska University Hospital, Stockholm, Sweden; Department of Surgical Sciences/Pain Research, Uppsala University, Uppsala, Sweden
Background/Purpose: The purpose with this study was to investigate whether the effects of a 4-week treatment with adalimumab (Humira™) could change previously reported aberrations in…
Abstract Number: 1343 • ACR Convergence 2022
Satisfaction with Rheumatoid Arthritis Care Is Related to Discordance with Providers’ Treatment Goals and Patients’ Reasons for Disagreement
Kelly O'Neill¹, Pamela Sinicrope², Cynthia Crowson³, Kathryne Marks⁴, Rachel Giblon⁵, Elena Myasoedova² and John Davis², ¹Rheumatoid Patient Foundation, Winter Springs, FL, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: We previously reported on the incidence of shared treatment goal discussions which are associated with disease activity (DA) improvement and satisfaction within rheumatology care.…
Abstract Number: 1398 • ACR Convergence 2022
Myokine Myostatin Is a Novel Predictor of One-year Radiographic Progression in Patients with Rheumatoid Arthritis
Jian-Zi Lin, Li-Juan Yang, Hong-Gui Li, Ai-Qi Zeng, Kui-Min Yang and Lie Dai, Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: Associations between rheumatoid arthritis (RA) and reduced skeletal muscle have been studied, and we firstly reported myopenia independently predict one-year radiographic progression in RA.…
Abstract Number: 1414 • ACR Convergence 2022
2022 Revision of the ACR/EULAR Remission Criteria for Rheumatoid Arthritis
Paul Studenic¹, Daniel Aletaha², Maarten de Wit³, Tanja Stamm⁴, Farideh Alasti⁵, Diane Lacaille⁶, Josef Smolen¹ and David Felson⁷, ¹Medical University of Vienna, Vienna, Austria, ²Medical University Vienna, Wien, Austria, ³Patient research partner, Amsterdam, Netherlands, ⁴Medical University of Vienna, CeMSIIS - Center for Medical Statistics, Informatics, and Intelligent Systems, Section for Outcomes Research, Wien, Austria, ⁵Medical University of Vienna, Department of Internal Medicine 3, Division of Rheumatology, Vienna, Austria, ⁶Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ⁷Boston University, Boston, MA
Background/Purpose: More than 10 years ago ACR and EULAR endorsed provisional criteria to define remission in RA, both Boolean and index-based. However, the agreement between…
Abstract Number: 1434 • ACR Convergence 2022
Retrospective Analysis of Tocilizumab-induced Neutropenia in Patients with Rheumatoid Arthritis
YoungEun Kim¹, Soo Min Ahn¹, Ji Seon Oh², Yong Gil Kim¹, Chang Keun Lee¹, Bin Yoo¹ and Seokchan Hong¹, ¹Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ²Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Neutropenia has been reported as one of the most frequent adverse events of tocilizumab. We conducted a retrospective cohort study to determine the risks…
Abstract Number: 1608 • ACR Convergence 2022
Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study
Huan Meng¹, Isaac Cheng², Byran P Yan¹, Alex PW Lee¹, Ho So¹ and Lai-shan Tam², ¹The Faculty of Medicine, CUHK, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong, China
Background/Purpose: Rheumatoid arthritis (RA) is associated with accelerated atherosclerosis driven by chronic inflammation. We have previously reported that achieving sustained disease activity score 28 (DAS28)…
Abstract Number: 1733 • ACR Convergence 2022
Granzyme K Elicits a New Pathway for Complement Activation in RA Synovium
Anna Jonsson¹, Carlos Donado², Emma Gomez-Rivas¹ and Michael Brenner³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: T cells are major drivers of rheumatoid arthritis (RA) pathogenesis. Most research has focused on CD4 T cells, but we have found that CD8+…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].